RE:RE:RE:RE:Big Pharma is facing a looming $236 Billion patent cliff
An acquistion of ONCY by a Big Pharma company will have the acquisitor be responsible for running any clinical trial with their oncology products which face loss of patent protection. These combinations with pelareorep would be "bundled" as a doublet for approval. Also subsequent "bundled" doublets with pelareorep approved in alternative indications would correspondly receive12 years of FDA market exclusivity based on pelareorep's eligibility for 12 years of exclusivity at the time of the "bundled treatment's" approval.